Intravenous Iron Drugs Market Report 2026

The intravenous iron drugs market size has grown rapidly in recent years. It will grow from $3.81 billion in 2025 to $4.22 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to high prevalence of iron deficiency anemia, limitations of oral iron absorption, hospital-based anemia management protocols, increased use in dialysis centers, clinical effectiveness of iv iron therapies.

The intravenous iron drugs market size is expected to see rapid growth in the next few years. It will grow to $6.34 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to rising chronic disease burden, growth in dialysis patient population, increasing cancer-related anemia cases, preference for rapid hemoglobin correction, expansion of outpatient infusion services. Major trends in the forecast period include increasing use in iron deficiency anemia management, rising adoption in chronic kidney disease patients, growing preference over oral iron therapies, expansion of single-dose iron formulations, higher utilization in oncology and gastroenterology.

The rising prevalence of chronic kidney disease (CKD) is expected to drive the growth of the intravenous iron drugs market in the coming years. Chronic kidney disease (CKD) is characterized by the gradual decline of kidney function over time, resulting in the kidneys’ reduced ability to efficiently filter waste and excess fluids from the bloodstream. The increasing prevalence of chronic kidney disease (CKD) is attributed to the growing rates of diabetes and hypertension, which gradually cause kidney damage. Intravenous iron drugs benefit chronic kidney disease patients by restoring iron levels, treating anemia, and improving hemoglobin concentrations, which enhances oxygen transport and decreases the reliance on erythropoiesis-stimulating agents. For example, in July 2025, Hamadan University of Medical Sciences, an Iran-based university, reported that the global number of newly diagnosed chronic kidney disease cases is projected to reach 25.06 million by 2030. Consequently, the rising prevalence of chronic kidney disease (CKD) is fueling the growth of the intravenous iron drugs market.

Major companies in the intravenous iron drugs market are concentrating on developing innovative therapies, such as intravenous (IV) iron replacement therapy, to enhance efficacy, safety, and patient outcomes. Intravenous (IV) iron replacement therapy is a medical treatment that administers iron directly into the bloodstream via an intravenous infusion. This therapy addresses iron deficiency and anemia, particularly in patients who are unable to tolerate or properly absorb oral iron supplements. For example, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical firm specializing in innovative drug development and healthcare solutions, announced that the U.S. Food and Drug Administration (FDA) had approved Injectafer (ferric carboxymaltose injection) for treating iron deficiency in adult patients with heart failure classified as New York Heart Association class II/III to improve exercise capacity. Injectafer is a commonly used intravenous iron therapy recognized for quickly replenishing iron levels in patients who cannot tolerate or do not respond adequately to oral iron supplements.

In June 2024, Menarini Asia-Pacific, a Singapore-based pharmaceutical and healthcare company, expanded its collaboration with Pharmacosmos A/S for an undisclosed amount. Through this expanded collaboration, Menarini obtained exclusive rights to commercialize MonoFer® in Singapore and Malaysia, bolstering its hematology portfolio and improving regional access to advanced IV iron therapies for managing iron deficiency. Pharmacosmos A/S is a Denmark-based pharmaceutical company that provides intravenous (IV) iron drugs.

Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd.

North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intravenous iron drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the intravenous iron drugs market by increasing the cost of imported active pharmaceutical ingredients, carbohydrate complexes, and formulation intermediates used in iv iron preparations. These impacts have been most pronounced in ferric carboxymaltose and iron sucrose segments, particularly in north america and europe where raw material sourcing is globally diversified. Asia-pacific manufacturers have experienced pricing pressure due to import dependence. However, tariffs have promoted domestic production of iv iron formulations and localized supply chains, improving availability and long-term cost control.

The intravenous iron drugs market research report is one of a series of new reports that provides intravenous iron drugs market statistics, including intravenous iron drugs industry global market size, regional shares, competitors with a intravenous iron drugs market share, detailed intravenous iron drugs market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous iron drugs industry. This intravenous iron drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Intravenous iron drugs consist of iron formulations delivered directly into the bloodstream to address iron deficiency and iron deficiency anemia, particularly in patients who cannot tolerate oral iron supplements or fail to respond sufficiently to them. These drugs function by quickly elevating iron levels, promoting hemoglobin synthesis, and enhancing oxygen transport, which helps relieve symptoms like fatigue and weakness.

The primary product categories for intravenous iron medications encompass iron dextran, iron sucrose, ferric carboxymaltose, and additional variants. Iron dextran serves as an injectable iron formulation designed for quick iron restoration in patients facing severe shortages, particularly when oral iron proves ineffective or poorly tolerated. These therapies address multiple conditions, including chronic kidney disease, inflammatory bowel disease, cancer, and various other disorders. Distribution occurs via hospital pharmacies, retail pharmacies, and online platforms.

The intravenous iron drugs market consists of sales of ferric gluconate, ferumoxytol, ferric derisomaltose, and sodium ferric gluconate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.